- GSK’s value is being questioned, but it may be undervalued, making it an attractive investment option.
- GSK announces availability of AREXVY, its Respiratory Syncytial Virus (RSV) vaccine, at all major US retail pharmacies.
- Settling the first Zantac cancer lawsuit could soothe investors and impact GSK’s stock positively.
- GSK has faced a 3.9% decline since the last earnings report, and its ability to rebound is uncertain.
- Legal disputes, such as the patent infringement lawsuit with Pfizer over RSV vaccines, pose risks to GSK’s business.
- The pharmaceutical industry faces potential challenges, including Medicare price negotiations by the Biden Administration.
investment score = chances characters count - risks characters count
- 2023-09-09 3 Pharmaceutical Stocks That Are Too Cheap to Ignore
- 2023-09-08 Unveiling GSK PLC (GSK)’s Value: Is It Really Priced Right? A Comprehensive Guide
- 2023-09-06 25 Most Globalized Countries in the World
- 2023-09-05 GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
- 2023-09-04 7 Stocks Hedge Funds Are Loading Up On
- 2023-08-29 Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations
- 2023-08-27 3 Growth Stocks to Ride the Coming Bull Market in Style
- 2023-08-26 Ken Fisher’s Top 15 Healthcare Stock Picks
- 2023-08-25 Glaxo (GSK) Down 3.9% Since Last Earnings Report: Can It Rebound?
- 2023-08-23 Trending tickers: Nvidia l Ocado l GSK l BP